Navigation Links
Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players

NEW YORK, July 6 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players

Injectable bio-implants provide rapid non-surgical treatments and offer effective replacement, restoration, or modulation of function to lost, damaged, or dysregulated physiology. Market opportunities for injectable bio-implants are high in an increasingly aging population that demands fast, effective, and safe treatments for age-related conditions. Both medical and aesthetic applications for biomaterials make the market opportunities for injectable bio-implants highly attractive for drug and device manufacturers. However, biocompatibility is crucial for any implantable biomaterial to integrate into the host anatomy and prevent an immunogenic response.

This report provides a comprehensive assessment and analysis of the current market for viscoaugmentation and viscosupplementation products and shows how research and development has expanded product choice and diversity among the relatively limited injectable medical devices that are approved.

The report also shows promising next-generation bio-implants and those in preclinical research and clinical development. It details the challenges of achieving biocompatibility and the technologies that have successfully emerged from biomaterials research. Additionally, the report details the major players, market opportunities, and emerging sectors of the field that are changing the landscape of injectable treatments with major applications in cosmetic dermatology and orthopedics. The report also shows how reformulation and product line extensions may be needed to succeed in an increasingly saturated market sector.

Key features of this report

  • Analysis of current biomaterials that have been developed as injectable medical devices
  • Evaluation of the barriers and problems associated with biocompatibility for developed biomaterial types
  • Identification of the current trends in injectable bio-implants for aesthetic and medical indications and how companies have expanded indications to increase revenues and portfolios
  • Analysis of next-generation products and how companies are reformulating products to improve clinical performance and patient attractiveness.
  • Assessment of approved injectable viscoaugmentation and viscosupplementation devices and the strategies employed to expand product lines

Scope of this report

  • Understanding of the key obstacles in research for biocompatibility in the development of injectable medical devices
  • Rationale for injectable device development and how biomaterials R&D has evolved to meet unmet needs in aesthetics and orthopedics
  • Up-to-date information on the marketed viscoaugmentation and viscosupplementation product sectors
  • Evaluates the key recent developments and activities of companies who are developing and licensing injectable bio-implant technologies.

Key Market Issues

  • Biocompatibility is a critical issue for commercial development of injectable bio-implants. Products that are not safe and biocompatible will fail in the marketplace.
  • Medical technology and device developers need to develop next-generation products that offer greater clinical benefits, value, and patient and physician preference.
  • Demand for more durable and adaptable formulations of bio-implants has led to expanded brands and indications in the market.
  • Reimbursement issues for injectable bio-implants in orthopedics is driving innovation to reformulate products that are more durable and hence more cost-effective.
  • Development efforts are underserved and focus on limited repertoire of biomaterials that reach the clinic.

Key findings from this report

  • Biocompatibility is a critical issue that challenges research and development of injectable bio-implants. Commercialized products are limited to collagens, hyaluronic acids, polymer formulations, and ceramics.
  • Demand for safer, more effective treatment options has stimulated R&D to produce a variety of same-type products differentiated by type, size, indication, and unmet needs mainly in cosmetic dermatology and orthopedics.
  • Commercial opportunities are evident for approved viscoaugmentation and viscosupplementation products in crossover fields where injectable bio-implants may be developed for a variety of diverse conditions.
  • Research and development themes are limited and few novel biomaterials have reached the clinic indicating upside potential for R&D in the field.
  • Companies are increasingly licensing and re-marketing products across therapeutic areas to maximize sales revenues, novelty, and product choice.

Key questions answered

  • What are key challenges in developing an injectable biomaterial and bio-implant?
  • What are the current commercialized product types and how have they evolved?
  • What are the key viscoaugmentation and viscosupplementation products and what key indications are they used for?
  • What are the trends in product development for approved injectable products?
  • How are companies optimizing their product lines?

Table of Contents

Opportunities in Non-surgical Bio-implants Executive summary 10

Injectable biomaterials 10

Viscoaugmentation 11

Viscosupplementation 12

Alloplastic injectable biomaterials: R&D 13

Chapter 1 Injectable biomaterials 16

Summary 16

Introduction 17

Development issues 18

Problems with biocompatibility 18

Design factors 20

Rationale for development of injectable biomaterials 22

Types of injectable biomaterials 22

Collagen 23

Hyaluronic acid 24

Hydrogels 25

Hydroxyapatite 26

Calcium phosphate ceramic pastes 27

Biopolymers 27

Adverse reactions associated with current injectable biomaterials 28

Ideal properties of injectable biomaterials 29

Chapter 2 Viscoaugmentation 32

Summary 32

Soft tissue viscoaugmentation bio-implants 33

Trends in injectable cosmetic treatments in the US 33

Primary indications for soft-tissue augmentation products 34

Collagen 35

Companies, products, and market activities 36

Allergan's Zyderm-Zyplast/Cosmoderm-Cosmoplast range 36

Recent industry activities: Evolence discontinued 37

Hyaluronic acid 38

Companies, products, and market activities 39

Adoderm 39

Allergan 39

Anteis 41

Anika Therapeutics 42

BioPolymer GmbH & Co. KG 43

Coapt Systems 45

Fidia Farmaceutici 46

KuhraVital Dermapharma 46

Laboratoires Filorga 46

L&M Aesthetic Equipment/Parpas Group 47

LCA Pharmaceutical 47

Hangzhou Gallop Biological Products 48

Novatex Bioengineering/Laboratoires Orgev 49

Johnson & Johnson/Mentor Corp. 50

Puragen 50

Merz Pharma/Merz Aesthetics 51

Q-Med 52

Nordic Aesthetics 54

Prollenium Medical Technologies 55

Rofil Medical/Philoderm Aesthetics 56

Teoxane Laboratoires 56

Biopolymers 57

Dimethicone/silicone oil 57

Companies, products, and market activities 58

Contura International 58

FzioMed 60

Polymekon 60

Suneva 61

ProCytech 62

Sanofi-Aventis 63

Generic polymeric soft tissue fillers 63

Ceramics/hybrid technologies 64

Companies, products, and market activities 64

BioForm Medical 64

Stiefel Laboratories/GlaxoSmithKline 65

Chapter 3 Viscosupplementation 68

Summary 68

Intra-articular injectable bio-implants 69

Marketed injectable products and company activities 70

Anika Therapeutics 70

Anteis 71

BioPolymer 71

Curasan 72

Ferring Pharmaceuticals 72

Fidia Farmaceutici 73

Genzyme Corp 73

LCA Pharmaceutical 74

Novatex Bioengineering 75

Ortho Biotech/Johnson & Johnson/Anika Therapeutics 76

Q-Med/Smith & Nephew 76

Sanofi-Aventis 77

Seikagaku/Smith & Nephew 77

TRB Chemedica 78

Generic sodium hyaluronate 79

Chapter 4 Alloplastic injectable biomaterials: R&D 82

Summary 82

Alloplastic injectable biomaterials: current R&D 83

Viscoaugmentation: cosmetic applications 83

Albiorex 83

FibroGen 84

Kythera Pharmaceuticals 84

Moma Therapeutics 84

Novatex Bioengineering 85

Prollenium Medical Technologies 85

Viscosupplementation: medical/surgical applications 85

Anika Therapeutics 86

Barrow Neurological Institute at St. Joseph's Hospital and Medical

Center, US 86

Biotechnology Institute IMASD 87

Genzyme Corp 87

Pioneer Surgical Technology 87

Prollenium Medical Technologies 88

Seikagaku 88

Considerations, insights, and recommendations 89

Appendix 91

Scope 91

Methodology 91

Glossary 92

Index 94

List of Figures

Figure 1.1: Potential adverse responses to implanted biomaterials 19

Figure 1.2: Essential design components for biocompatibility of implantable biomaterials 20

Figure 1.3: Types of marketed injectable biomaterials 23

Figure 1.4: Medical applications and benefits of hydrogels 26

Figure 1.5: Potential adverse reactions associated with injectable biomaterials 29

Figure 2.6: Trends in injectable treatments in the US, 2003–2009 34

Figure 2.7: Primary indications for soft tissue dermal fillers 35

List of Tables

Table 1.1: Basic properties and medical applications of biomaterials 18

Table 1.2: Medical applications of hyaluronic acid 25

Table 1.3: Medical applications of biopolymers 28

Table 2.4: Marketed collagen-based injectable products 36

Table 2.5: Main indications for Allergan's collagen-based injectable products 37

Table 2.6: Adoderm's hyaluronic acid-based injectable products 39

Table 2.7: Allergan's hyaluronic acid-based injectable products 41

Table 2.8: Anteis' hyaluronic acid-based injectable products 42

Table 2.9: Anika Therapeutics' hyaluronic acid-based injectable products 43

Table 2.10: Biopolymer's marketed hyaluronic acid-based injectable products 44

Table 2.11: Coapt Systems' marketed hyaluronic acid-based injectable products 45

Table 2.12: KuhraVital's marketed hyaluronic acid-based injectable products 46

Table 2.13: Laboratoires Filorga's marketed hyaluronic acid-based injectable products 47

Table 2.14: L&M Aesthetic's marketed hyaluronic acid-based injectable products 47

Table 2.15: LCA Pharma's marketed hyaluronic acid-based injectable products 48

Table 2.16: HGBP's marketed hyaluronic acid-based injectable products 49

Table 2.17: Novatex's hyaluronic acid-based injectable products 50

Table 2.18: J&J's marketed hyaluronic acid-based injectable products 50

Table 2.19: Merz Pharma's marketed hyaluronic acid-based injectable products 51

Table 2.20: Q-Med's marketed hyaluronic acid-based injectable products 52

Table 2.21: Nordic Aesthetics' marketed hyaluronic acid-based injectable products 54

Table 2.22: Prollenium's marketed hyaluronic acid-based injectable products 55

Table 2.23: Rofil Medical/Philiderm Aesthetics' marketed hyaluronic acid-based injectable products 56

Table 2.24: Teoxane's marketed hyaluronic acid-based injectable products 57

Table 2.25: Contura's marketed polymer-based injectable products 59

Table 2.26: FzioMed's marketed polymer-based injectable products 60

Table 2.27: Polymekon's marketed polymer-based injectable products 60

Table 2.28: Suneva's marketed polymer-based injectable products 62

Table 2.29: ProCytech's marketed polymer-based injectable products 62

Table 2.30: Sanofi-Aventis' marketed polymer-based injectable products 63

Table 2.31: BioForm Medical's injectable ceramic-based products 65

Table 2.32: Stiefel Laboratories/GSK's injectable ceramic-based products 66

Table 3.33: Application of biomaterials for orthopedic applications 69

Table 4.34: Selected allosteric viscoaugmentation products in development 83

Table 4.35: Selected allosteric viscosupplementation products in development 86

To order this report:

Biomaterial Industry: Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players

Biomaterial Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):